Search

Search Constraints

You searched for: Author/Creator Taniguchi, Hiroya

Search Results

21. Phase I Study of Alternate‐Day Administration of S‐1, Oral Leucovorin, and Bevacizumab for Refractory Metastatic Colorectal Cancer. (17th June 2020)

22. Practical considerations in the use of regorafenib in metastatic colorectal cancer. (October 2020)

24. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study. (11th September 2017)

25. Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G). (August 2020)

26. Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study). (February 2021)

27. Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer. Issue 6 (13th November 2019)

29. Recommendations related to the analytical equivalence assessment of gene panel testing. Issue 10 (19th August 2022)

30. SCRUM‐Japan GI‐SCREEN and MONSTAR‐SCREEN: Path to the realization of biomarker‐guided precision oncology in advanced solid tumors. Issue 11 (16th September 2021)